Publication:
Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.

Simple item page
dc.contributor.authorGodoy-Ortiz, Ana
dc.contributor.authorSanchez-Muñoz, Alfonso
dc.contributor.authorChica Parrado, Maria Rosario
dc.contributor.authorÁlvarez, Martina
dc.contributor.authorRibelles, Nuria
dc.contributor.authorRueda Dominguez, Antonio
dc.contributor.authorAlba, Emilio
dc.date.accessioned2024-02-10T20:02:24Z
dc.date.available2024-02-10T20:02:24Z
dc.date.issued2019-10-29
dc.description.abstractThe main obstacle for designing effective treatment approaches in breast cancer is the extensive and the characteristic heterogeneity of this tumor. The vast majority of critical genomic changes occurs during breast cancer progression, creating a significant variability within primary tumors as well as between the primary breast cancer and their metastases, a hypothesis have already demonstrated in retrospective studies (1). A clear example of this is the HER2-positive breast cancer. In these tumors, we can find all of the transcriptional subtypes of breast cancer, even the basal like or luminal A subtypes. Although the HER2-enriched is the most representative transcriptional subtype in the HER2-positive breast cancer, we can find it too in breast cancers with HER2-negative status. This intrinsic subtype shows a high expression of the HER2 and is associated with proliferation-related genes clusters, among other features. Therefore, two hypotheses can be suggested. First, the HER2 amplification can be a well-defined driver event present in all of the intrinsic subtypes, and not a subtype marker isolated. Secondly, HER2-enriched subtype can have a distinctive transcriptional landscape independent of HER2 amplification. In this review, we present an extensive revision about the last highlights and advances in clinical and genomic settings of the HER2-positive breast cancer and the HER2-enriched subtype, in an attempt to improving the knowledge of the underlying biology of both entities and to explaining the intrinsic heterogeneity of HER2-positive breast cancers.
dc.format.page1124es_ES
dc.format.volume9es_ES
dc.identifier.doi10.3389/fonc.2019.01124
dc.identifier.issn2234-943X
dc.identifier.journalFrontiers in oncologyes_ES
dc.identifier.otherhttp://hdl.handle.net/10668/14703
dc.identifier.pubmedID31737566es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/17925
dc.language.isoeng
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectHER2-enriched
dc.subjectHER2-positive
dc.subjectBreast cancer
dc.subjectHeterogeneity
dc.subjectIntrinsic subtype
dc.subjectMolecular
dc.titleDeciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication
Files
Collections
IBIMA-Plataforma BIONAND - Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (Andalucía)